Selective degradation of mitochondria by mitophagy - PubMed (original) (raw)
Review
Selective degradation of mitochondria by mitophagy
Insil Kim et al. Arch Biochem Biophys. 2007.
Abstract
Mitochondria are the essential site of aerobic energy production in eukaryotic cells. Reactive oxygen species (ROS) are an inevitable by-product of mitochondrial metabolism and can cause mitochondrial DNA mutations and dysfunction. Mitochondrial damage can also be the consequence of disease processes. Therefore, maintaining a healthy population of mitochondria is essential to the well-being of cells. Autophagic delivery to lysosomes is the major degradative pathway in mitochondrial turnover, and we use the term mitophagy to refer to mitochondrial degradation by autophagy. Although long assumed to be a random process, increasing evidence indicates that mitophagy is a selective process. This review provides an overview of the process of mitophagy, the possible role of the mitochondrial permeability transition in mitophagy and the importance of mitophagy in turnover of dysfunctional mitochondria.
Figures
Figure 1. Scheme of Mitophagy
Atg12-Atg5-Atg16 and LC3 complexes localize to isolation membranes. In nutrient deprivation (starvation), isolation membranes target individual mitochondria by unknown signals in a process inhibited by the PI3K inhibitors, 3-methyladenine (3MA) and wortmannin. Isolation membranes completely envelop individual mitochondria to form double membrane vesicles (autophagosomes). After this sequestration, mitochondria depolarize in a CsA and NIM811 sensitive fashion, and Atg12-Atg5/Atg16 complexes are released from the autophagosomal surface. Autophagosomes then acidify and fuse with lysosomal vesicles to form autolysosomes. Lysosomal hydrolases digest the inner autophagosomal membrane and degrade LC3 trapped inside autophagosomes. Remaining LC3 on the surface of autophagosomes is released. After mitochondrial damage, mitochondria first depolarize and then are recognized and sequestered by isolation membranes recognizing unknown markers on the damaged mitochondria. 3MA and wortmannin do not inhibit this process but actually seem to augment it. In both pathways, sequestered mitochondria are completely digested and their molecular components recycled to the cytoplasm.
Figure 2. Models of the Permeability Transition Pore
In one model (A), the PT pore is composed of ANT from the inner membrane (IM), CypD from the matrix, VDAC from the outer membrane (OM) and other proteins, including hexokinase (HK), creatine kinase (CK) and Bax, a proapoptotic Bcl2 family member. Ca2+, inorganic phosphate (Pi), ROS and oxidized pyridine nucleotides NAD(P)+ and glutathione (GSSG) promote PT pore opening, whereas CsA, Mg2+ and pH less than 7 inhibit opening. In an alternative model (B), PT pores form from misfolding and aggregation of damaged mitochondrial membrane proteins at hydrophilic surfaces facing the hydrophobic membrane bilayer. CypD and other chaperones bind to the nascent PT pores and block conductance of solutes through the aqueous channels formed by the protein clusters. High Ca2+ opens these regulated channels acting through CypD, an effect blocked by CsA. As misfolded protein clusters exceeds the number of chaperones available to regulate them, constitutively open unregulated channels form that are not inhibited by CsA.
Figure 3. Mitochondrial Depolarization in Hepatocytes after Nutrient Deprivation
Cultured rat hepatocytes were loaded with MitoTracker Green and TMRM and imaged by confocal microscopy before (Baseline) and 60 min after (Nutrient Deprivation) changing from complete growth medium to a modified Krebs-Ringer buffer containing glucagon. Green-fluorescing structures (circles) in the overlay images are newly depolarized mitochondria.
Figure 4. Mitophagy During Nutrient Deprivation in Hepatocytes from Transgenic GFP-LC3 Mice
Hepatocytes were loaded with TMRM to monitor mitochondrial membrane potential and subjected to nutrient deprivation in modified Krebs-Ringer buffer containing glucagon. In the time-lapse confocal images, note green-fluorescing GFP-LC3 enveloping and then sequestering a red-fluorescing mitochondrion (arrows). After sequestration, the mitochondrion loses its red fluorescence, indicating depolarization.
Figure 5. Photodamage-induced Mitophagy
GFP-LC3 transgenic hepatocytes were loaded with TMRM (Baseline), and 5 to 10 mitochondria were exposed to a pulse of 488-nm laser light at full power (circles). Mitochondria lost red TMRM within a minute, indicating mitochondrial depolarization. After 30 min, green GFP-LC3 fluorescence localized to the region where mitochondria were damaged. After 55 min, the photodamaged mitochondria were sequestered into GFP-LC3-labeled autophagosomes, which indicated that the damaged mitochondria were selectively targeted for mitophagy.
Figure 6. Progression of Mitophagy, Apoptosis and Necrosis
Inducers of the MPT include NAD(P)+, GSSG, ROS, Ca2+, and mutations of mtDNA (mtDNA_X_). As the MPT involves an increasing proportion of mitochondria, cellular responses progress from mitophagy, a repair mechanism, to apoptosis driven by release of cytochrome c and other proapoptotic factors from mitochondria, and finally to necrosis due to ATP depletion. As ATP becomes depleted, mitophagy and apoptosis become inhibited.
References
- Saraste M. Oxidative phosphorylation at the fin de siecle. Science. 1999;283:1488–1493. - PubMed
- Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979;59:527–605. - PubMed
- Turrens JF, Alexandre A, Lehninger AL. Ubisemiquinone is the eletron donor for superoxide formation by complex III of heart mitochondria. Arch Biochem Biophys. 1985;237:408–411. - PubMed
- Gores GJ, Flarsheim CE, Dawson TL, Nieminen AL, Herman B, Lemasters JJ. Swelling, reductive stress, and cell death during chemical hypoxia in hepatocytes. Am J Physiol. 1989;257:C347–C354. - PubMed
- Dawson TL, Gores GJ, Nieminen AL, Herman B, Lemasters JJ. Mitochondria as a source of reactive oxygen species during reductive stress in rat hepatocytes. Am J Physiol. 1993;264:C961–C967. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 DK059340-03/DK/NIDDK NIH HHS/United States
- R37 DK037034-16/DK/NIDDK NIH HHS/United States
- R37 DK037034-22/DK/NIDDK NIH HHS/United States
- P30 DK034987-169004/DK/NIDDK NIH HHS/United States
- P30 DK034987-159004/DK/NIDDK NIH HHS/United States
- 1 P01 DK59340/DK/NIDDK NIH HHS/United States
- R01 DK037034-23/DK/NIDDK NIH HHS/United States
- R37 DK037034-19/DK/NIDDK NIH HHS/United States
- P30 DK034987/DK/NIDDK NIH HHS/United States
- P30 DK034987-199004/DK/NIDDK NIH HHS/United States
- P01 DK059340-02/DK/NIDDK NIH HHS/United States
- P30 DK034987-209004/DK/NIDDK NIH HHS/United States
- P01 DK059340-04/DK/NIDDK NIH HHS/United States
- P30 DK034987-17S19004/DK/NIDDK NIH HHS/United States
- P50 AA011605/AA/NIAAA NIH HHS/United States
- P30 DK034987-189004/DK/NIDDK NIH HHS/United States
- R37 DK037034-18/DK/NIDDK NIH HHS/United States
- P30 DK034987-219004/DK/NIDDK NIH HHS/United States
- C06 RR015455/RR/NCRR NIH HHS/United States
- R01 DK073336-03/DK/NIDDK NIH HHS/United States
- S10 RR013689-01A1/RR/NCRR NIH HHS/United States
- R37 DK037034-15/DK/NIDDK NIH HHS/United States
- P50 AA011605-029003/AA/NIAAA NIH HHS/United States
- C06 RR015455-01A1/RR/NCRR NIH HHS/United States
- R01 DK037034/DK/NIDDK NIH HHS/United States
- R01 DK073336/DK/NIDDK NIH HHS/United States
- P01 DK059340-05/DK/NIDDK NIH HHS/United States
- 2-R01 DK37034/DK/NIDDK NIH HHS/United States
- P01 DK059340-01/DK/NIDDK NIH HHS/United States
- R37 DK037034-20/DK/NIDDK NIH HHS/United States
- P30 DK034987-249004/DK/NIDDK NIH HHS/United States
- P30 DK034987-239004/DK/NIDDK NIH HHS/United States
- P01 DK059340-020002/DK/NIDDK NIH HHS/United States
- P50 AA011605-059003/AA/NIAAA NIH HHS/United States
- P30 DK034987-16S19004/DK/NIDDK NIH HHS/United States
- R01 DK073336-02/DK/NIDDK NIH HHS/United States
- R37 DK037034-14/DK/NIDDK NIH HHS/United States
- P50 AA011605-019003/AA/NIAAA NIH HHS/United States
- P50 AA011605-039003/AA/NIAAA NIH HHS/United States
- R37 DK037034-17/DK/NIDDK NIH HHS/United States
- P01 DK059340-010002/DK/NIDDK NIH HHS/United States
- P30 DK034987-179004/DK/NIDDK NIH HHS/United States
- R37 DK037034-21/DK/NIDDK NIH HHS/United States
- P50 AA011605-049003/AA/NIAAA NIH HHS/United States
- R01 DK073336-01A2/DK/NIDDK NIH HHS/United States
- P01 DK059340/DK/NIDDK NIH HHS/United States
- P30 DK034987-229004/DK/NIDDK NIH HHS/United States
- R37 DK037034/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources